Orlistat Market Overview
Global Orlistat Market was valued at USD 3.62 billion in 2024 and is expected to reach USD 7.02 billion by the year 2035, at a increasing CAGR of 6.2% (2025-2035).
The growing number of weight-loss awareness initiatives is likely to be a significant driver for the growth of Orlistat market. Mainly, orlistat is used as an anti-obesity medication. The primary function of Orlistat is to inhibit fat absorption from the human diet. It limits fat absorption by acting as a lipase inhibitor, resulting in a reduction in calorie intake. Orlistat works by blocking pancreatic and gastric lipases, which are enzymes in the gut that break down triglycerides. When lipase activity is inhibited, dietary triglycerides are not digested into absorbable-free fatty acids and instead stay unaltered.
In most of the regions across globe, obesity-related issues have been a growing concern in the recent years. Orlistat also lowers blood pressure and inhibits the formation of type 2 diabetes in obese population. Orlistat medication does not allow an individual to regain lost weight and does not block the absorption of fats from non-fat foods and sugar.
Major Growth Drivers: Orlistat Market
Over the forecasted period, a robust pipeline of the orlistat drug is projected to enhance market growth. Furthermore, Orlistat, developed by the University of Texas South Western Medical Center, has been in phase 2 testing since 2015. Orlistat is a medication used to treat type 1 hyperlipoproteinemia. Lipoprotein lipase deficiency causes hyperlipoproteinemia type 1. The University of Texas South Western Medical Canters’ SLx-4090 is under phase 2 testing to see how well it works in conjunction with Orlistat. SLx-4090 is used to treat elevated blood fat levels, which are most commonly seen in people with hyperlipoproteinemia type 1.
The rising prevalence of obesity and its related diseases is projected to drive orlistat market expansion. According to a National Family Health Survey done in 2015 in India, over 9.8 million men and over 20 million women are obese. India has the world's second-highest rate of obese children, with the number steadily growing by 3-5 million patients per year.
Challenges : Orlistat Market
Health risks such as the risk of psychiatric disorder and stroke are expected to have a negative impact on market growth over the forecast period. Innumerable anti-obesity drugs approved in the last decade, including Knoll and Acomplia (rimonabant), have been withdrawn due to long-term side effects such as suicidal thoughts, depression, and cardiovascular problems. Due to the previously mentioned factors, healthcare providers have a negative impression of anti-obesity drugs and do not recommend them to consumers.
The market for orlistat and anti-obesity drugs is expected to grow slowly due to high attrition rates in the recent years. The transition of therapeutic goods from phase one through market is difficult because more than 80% of drugs are discontinued before reaching pre-registration. It will result in a low number of representative drugs in later stages of development.
Market Segmentation
Geographically, Asia-Pacific accounted for the largest market share in 2018 and is anticipated to maintain its dominance by the end of 2024. Asia-Pacific is expected to exhibit the highest CAGR of 6.2% over the forecast period.
Players Covered in Orlistat Market are :
- Roche
- GSK group
- Teva
- Sandoz(Novartis)
- STADA-VN J.V.Co. Ltd
- Hexal AG
- National Company for Pharmaceutical Industry
- Lunan Pharmaceutical Group Corporation
- ZEIN pharmaceutical
- HISUN
- Taj Pharmaceuticals Ltd
- Kabir Life Sciences & Research
- DM Pharma
- China Zhongshan Pharm and other Active players.
|
Global Orlistat Market |
|||
|
Base Year: |
2024 |
Forecast Period: |
2025-2035 |
|
Historical Data: |
2018 to 2023 |
Market Size in 2024: |
USD 3.62 Bn. |
|
Forecast Period 2025-35 CAGR: |
6.2% |
Market Size in 2035: |
USD 7.02 Bn. |
|
Segments Covered: |
By Type |
|
|
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Orlistat Market by Type (2018-2035)
4.1 Orlistat Market Snapshot and Growth Engine
4.2 Market Overview
4.3 120 mg
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
4.3.3 Key Market Trends, Growth Factors, and Opportunities
4.3.4 Geographic Segmentation Analysis
4.4 60 mg
Chapter 5: Orlistat Market by Distribution (2018-2035)
5.1 Orlistat Market Snapshot and Growth Engine
5.2 Market Overview
5.3 Channel
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units
5.3.3 Key Market Trends, Growth Factors, and Opportunities
5.3.4 Geographic Segmentation Analysis
5.4 Hospital Pharmacies
5.5 Online Pharmacies
5.6 Retail Pharmacies
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Orlistat Market Share by Manufacturer (2024)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 MICROSOFT (US)
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 HTC (TAIWAN)
6.4 GOOGLE (US)
6.5 APPLE (US)
6.6 PTC (US)
6.7 META PLATFORMS (US)
6.8 QUALCOMM TECHNOLOGIES (US) OTHER ACTIVE PLAYERS
Chapter 7: Global Orlistat Market By Region
7.1 Overview
7.2. North America Orlistat Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size by Type
7.2.4.1 120 mg
7.2.4.2 60 mg
7.2.5 Historic and Forecasted Market Size by Distribution
7.2.5.1 Channel
7.2.5.2 Hospital Pharmacies
7.2.5.3 Online Pharmacies
7.2.5.4 Retail Pharmacies
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Orlistat Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size by Type
7.3.4.1 120 mg
7.3.4.2 60 mg
7.3.5 Historic and Forecasted Market Size by Distribution
7.3.5.1 Channel
7.3.5.2 Hospital Pharmacies
7.3.5.3 Online Pharmacies
7.3.5.4 Retail Pharmacies
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Russia
7.3.6.2 Bulgaria
7.3.6.3 The Czech Republic
7.3.6.4 Hungary
7.3.6.5 Poland
7.3.6.6 Romania
7.3.6.7 Rest of Eastern Europe
7.4. Western Europe Orlistat Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size by Type
7.4.4.1 120 mg
7.4.4.2 60 mg
7.4.5 Historic and Forecasted Market Size by Distribution
7.4.5.1 Channel
7.4.5.2 Hospital Pharmacies
7.4.5.3 Online Pharmacies
7.4.5.4 Retail Pharmacies
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 The Netherlands
7.4.6.5 Italy
7.4.6.6 Spain
7.4.6.7 Rest of Western Europe
7.5. Asia Pacific Orlistat Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size by Type
7.5.4.1 120 mg
7.5.4.2 60 mg
7.5.5 Historic and Forecasted Market Size by Distribution
7.5.5.1 Channel
7.5.5.2 Hospital Pharmacies
7.5.5.3 Online Pharmacies
7.5.5.4 Retail Pharmacies
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Orlistat Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size by Type
7.6.4.1 120 mg
7.6.4.2 60 mg
7.6.5 Historic and Forecasted Market Size by Distribution
7.6.5.1 Channel
7.6.5.2 Hospital Pharmacies
7.6.5.3 Online Pharmacies
7.6.5.4 Retail Pharmacies
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkiye
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Orlistat Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size by Type
7.7.4.1 120 mg
7.7.4.2 60 mg
7.7.5 Historic and Forecasted Market Size by Distribution
7.7.5.1 Channel
7.7.5.2 Hospital Pharmacies
7.7.5.3 Online Pharmacies
7.7.5.4 Retail Pharmacies
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
|
Global Orlistat Market |
|||
|
Base Year: |
2024 |
Forecast Period: |
2025-2035 |
|
Historical Data: |
2018 to 2023 |
Market Size in 2024: |
USD 3.62 Bn. |
|
Forecast Period 2025-35 CAGR: |
6.2% |
Market Size in 2035: |
USD 7.02 Bn. |
|
Segments Covered: |
By Type |
|
|
|
By Distribution Channel |
|
||
|
By Region |
|
||
|
Key Market Drivers: |
|
||
|
Key Market Restraints: |
|
||
|
Key Opportunities: |
|
||
|
Companies Covered in the report: |
|
||
